Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

PURPOSE: The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic pancreatic cancer. These encouraging data led Cancer and Leukemia Group B (CALGB) to conduct a double-blind, placebo-c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kindler, Hedy Lee, Niedzwiecki, Donna, Hollis, Donna, Sutherland, Susan, Schrag, Deborah, Hurwitz, Herbert, Innocenti, Federico, Mulcahy, Mary Frances, O'Reilly, Eileen, Wozniak, Timothy F., Picus, Joel, Bhargava, Pankaj, Mayer, Robert J., Schilsky, Richard L., Goldberg, Richard M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2010
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917317/
https://ncbi.nlm.nih.gov/pubmed/20606091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.28.1386
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars